Tepotinib (Tepmetko®). HTA ID: 22025

Assessment Status NCPE assessment ongoing
HTA ID 22025
Drug Tepotinib
Brand Tepmetko®
Indication For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Assessment Process
Rapid review commissioned 22/04/2022
Rapid review completed 30/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tepotinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 13/09/2022
Full submission received from Applicant 10/01/2023
Preliminary review sent to Applicant 23/05/2023
NCPE assessment re-commenced 22/06/2023